期刊
NEUROTHERAPEUTICS
卷 16, 期 2, 页码 263-286出版社
SPRINGER
DOI: 10.1007/s13311-018-00696-y
关键词
Spinocerebellar ataxia; SCA; polyglutamine disorders; gene therapy; stem cell-based therapy; antisense oligonucleotides
资金
- Dutch SCA1 Families Fund
- Dutch Brain Foundation (Nederlandse Hersenstichting) grant [HA2016-02-02]
- VENI grant from the Netherlands Organization of Scientific Research [91615080]
- AFM Telethon [20577]
Autosomal dominant cerebellar ataxias (ADCAs) are a group of neurodegenerative disorders characterized by degeneration of the cerebellum and its connections. All ADCAs have progressive ataxia as their main clinical feature, frequently accompanied by dysarthria and oculomotor deficits. The most common spinocerebellar ataxias (SCAs) are 6 polyglutamine (polyQ) SCAs. These diseases are all caused by a CAG repeat expansion in the coding region of a gene. Currently, no curative treatment is available for any of the polyQ SCAs, but increasing knowledge on the genetics and the pathological mechanisms of these polyQ SCAs has provided promising therapeutic targets to potentially slow disease progression. Potential treatments can be divided into pharmacological and gene therapies that target the toxic downstream effects, gene therapies that target the polyQ SCA genes, and stem cell replacement therapies. Here, we will provide a review on the genetics, mechanisms, and therapeutic progress in polyglutamine spinocerebellar ataxias.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据